Itovebi is supplied as a tablet in 2 dosage strengths: 3mg and 9mg. Patients should be selected for treatment based on the presence of 1 or more PIK3CA mutations in plasma specimens. The FDA has ...

The Breakthrough Therapy designation is supported by positive interim data from the phase 2b VANTAGE study (ClinicalTrials.gov Identifier: NCT05050136) that evaluated the efficacy and safety of ...

HealthDay News — Dronabinol is safe and effective for the treatment of Alzheimer disease with agitation (Agit-AD), according to a study presented at the annual meeting of the International ...

"Rigorous evidence suggests that the FDA's most serious ongoing youth antidepressant warnings have not had the intended outcome of increased monitoring for suicidal thoughts and behaviors." HealthDay ...

The impact of Hurricane Helene has led to a temporary supply disruption at the Baxter facility in Marion, North Carolina. The facility manufactures a significant portion of IV solutions, irrigation ...

The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for elinzanetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

The Food and Drug Administration (FDA) has granted Fast Track designation to liafensine (DB104) for patients with treatment-resistant depression (TRD).

The Healgen at-home test is the first OTC test for influenza detection to be granted marketing authorization outside of an ...

HealthDay News — Implementation of a tobacco-free generation could substantially reduce global lung cancer mortality, according to a study published in the October issue of The Lancet Public Health.

Importantly, the CDC data remains preliminary and could change because state data lags as coroners and medical examiners conclude death investigations.

HealthDay News — Artificial intelligence (AI) scores may be able to estimate the risk for future breast cancer and lead to earlier diagnosis, according to a study published online October 3 in JAMA ...

HealthDay News — Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) results in a deep and durable response, according to a study published online ...